Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 7/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.55 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31558346 | 1.00 | LTB4R (0.55) | LTB4RLTB4R2GBA1OPRM1OPRD1 | |
| SCHEMBL31558354 | 0.83 | ALDH1A1 (0.43) | LTB4RLTB4R2GBA1 | |
| SCHEMBL31558347 | 0.83 | LTB4R (0.40) | LTB4RLTB4R2 | |
| SCHEMBL31558350 | 0.83 | LTB4R (0.53) | LTB4RLTB4R2GBA1SLC22A1PRCP | |
| SCHEMBL4666507 | 0.79 | BLM (0.43) | LTB4RLTB4R2OPRM1BLMTSHR | |
| SCHEMBL17539095 | 0.79 | BLM (0.43) | LTB4RLTB4R2OPRM1BLMTSHR | |
| SCHEMBL24821521 | 0.78 | BLM (0.42) | OPRM1BLMTSHRSIGMAR1 | |
| SCHEMBL2214776 | 0.78 | HTR2A (0.46) | BLMTSHR | |
| SCHEMBL8151404 | 0.78 | SLC6A4 (0.42) | LTB4RLTB4R2BLMTSHRSIGMAR1 | |
| SCHEMBL8151400 | 0.78 | SLC6A4 (0.42) | LTB4RLTB4R2BLMTSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | LTB4R 3845/4885LTB4R2 4204/4885GBA1 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.